| Market Cap | 1.80B+166.0% |
| Revenue (ttm) | 1.56M-62.3% |
| Net Income | -121.08M-6.9% |
| EPS | -0.80+14.9% |
| Shares Out | 171.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,151,767 |
| Open | 10.26 |
| Previous Close | 10.00 |
| Day's Range | 9.78 - 10.68 |
| 52-Week Range | 2.24 - 12.54 |
| Beta | 2.23 |
| Analysts | Buy |
| Price Target | 13.67(+30.44%) |
| Earnings Date | Nov 12, 2026 |
Insiders here have filed 5 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About ABSI
Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
5 firms rating ABSI in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 12, 2026Earnings report
Ask Barron about ABSI
$ABSI stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ABSI holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ABSI's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ABSI Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ABSI Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Personnel | $9.57M | 50.68% |
| Stock-based compensation | $5.25M | 27.78% |
| General & administrative | $4.03M | 21.35% |
| Other (gain)/loss, net | $37.00K | 0.20% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ABSI patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ABSI from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ABSI
| ETF | Est. Holding Size |
|---|---|
| ARKGARK Genomic Revolution ETF | $109.95M |
| VTIVanguard Morningstar Total Stock Market ETF | $54.72M |
| XBIState Street SPDR S&P Biotech ETF | $51.67M |
| IWMiShares Russell 2000 ETF | $38.62M |
| VXFVanguard Extended Market ETF | $19.63M |
| IWOiShares Russell 2000 Growth ETF | $11.75M |
Estimated from each fund’s disclosed top holdings × AUM
ABSI Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ABSI’s recent data — informational, not investment advice
What’s Behind the Score
News check: Mix of analyst upgrade (Jefferies Buy rating, $14 PT) and positive trial data offset by recent stock weakness; net bullish tone on fundamentals.